Associated Papers
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas.
Dawed AY et al.
Diabetes Care, 2021
Investigating the influence of relevant pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of orally administered docetaxel combined with ritonavir.
van Eijk M et al.
The Pharmacogenomics Journal, 2021
UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2020
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.
Wagner JB et al.
Clinical and Translational Science, 2020
Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics.
Nie Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2020
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Genetic variability and population diversity of the human SLCO (OATP) transporter family.
Zhang B et al.
Pharmacological Research, 2019
A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.
Lu C et al.
Cold Spring Harbor Molecular Case Studies, 2016
Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1.
Nies AT et al.
Genome Medicine, 2013
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients.
Chew SC et al.
British Journal of Clinical Pharmacology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK et al.
European Journal of Clinical Pharmacology, 2011
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Schwarz UI et al.
Pharmacogenetics and Genomics, 2011
Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population.
Laitinen A et al.
Basic & Clinical Pharmacology & Toxicology, 2011
The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.
Picard N et al.
Clinical Pharmacology and Therapeutics, 2010
Pharmacogenetic pathway analysis of docetaxel elimination.
Baker SD et al.
Clinical Pharmacology and Therapeutics, 2009
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Franke RM et al.
Clinical Pharmacology and Therapeutics, 2008
Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE et al.
Molecular Pharmaceutics, 0